Gastroparesis future or investigational therapies

Jump to navigation Jump to search

Gastroparesis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Gastroparesis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Gastroparesis future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Gastroparesis future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Gastroparesis future or investigational therapies

CDC on Gastroparesis future or investigational therapies

Gastroparesis future or investigational therapies in the news

Blogs on Gastroparesis future or investigational therapies

Directions to Hospitals Treating Gastroparesis

Risk calculators and risk factors for Gastroparesis future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]

Overview

Future or investigational therapies

  • In patients with diabetic gastroparesis, ghrelin and motilin receptors, are the two key pharmacological targets, that have emerged for novel therapeutic options.
  • The intravenously administered cyclic ghrelin analog, TZP-101, was demonstrated to accelerate gastric emptying and improve symptom severity when compared with placebo.
  • When studied in a phase IIa clinical trial, the oral counterpart, TZP-102, showed promise in that significant improvement in symptoms were seen (although there was no change in gastric emptying) after 4 weeks of treatment
  • The follow-up 12-week phase IIb trial 76 failed to demonstrate a benefit; however, and it seems further investigation of this agent is not being pursued.
  • Relamorelin (RM-131) is a synthetic small molecule ghrelin agonist which, when administered as a one-time subcutaneous injection, has been demonstrated to accelerate gastric emptying in patients with diabetic GP.
  • In a 4-week, phase II clinical trial, twice daily relamorelin improved gastric emptying as measured by breath testing and improved subjective vomiting severity as compared with placebo.
  • Other GP symptom measurements were not significantly improved, however, Camicinal (GSK962040) is a small molecule selective motilin receptor agonist that was developed based on the mechanism and molecular structure of macrolide antibiotics.
  • Camicinal improves gastric empting in diabetic GP as demonstrated in several phase I clinical trials 80 and preliminary results of a phase II clinical trial demonstrates significant symptom improvement above placebo.

References

Template:WH Template:WS